Screener
NeoGenomics NEO Impairment Charges
Impairment Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001077183-26-000059
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| General and administrative | 63,613 | 71,747 | 129,354 | 139,954 |
| Research and development | 10,761 | 9,023 | 20,295 | 19,204 |
| Sales and marketing | 27,275 | 24,075 | 51,105 | 46,758 |
| Impairment charges (Note 5) | — | 20,041 | — | 20,041 |
| Total operating expenses | 101,649 | 124,886 | 200,754 | 225,957 |
| LOSS FROM OPERATIONS | (9,771) | (47,628) | (28,012) | (75,453) |
| Interest income | 1,214 | 2,263 | 2,487 | 5,984 |
| Interest expense | (781) | (933) | (1,379) | (2,551) |
Item 1. Financial Statements (unaudited)
FAQ
- What is NeoGenomics's impairment charges?
- NeoGenomics (NEO) reported impairment charges of $0 in Q2 2026.
- How has NeoGenomics's impairment charges changed year-over-year?
- NeoGenomics's impairment charges decreased by 100.0% year-over-year, from $20.04M to $0.
- What does impairment charges mean?
- Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.
Ask your AI about NeoGenomics's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude